Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.37
+10.56 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
33
34
Next >
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
March 16, 2023
It's still unclear whether CMS will include those drugs in its negotiation list.
Via
Investor's Business Daily
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today
March 16, 2023
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
March 14, 2023
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
March 09, 2023
Via
Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
March 07, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
March 06, 2023
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 22, 2023
Via
Benzinga
2 Biotech Stocks That Could Help Set You Up for Life
February 11, 2023
The two companies have seen similar share growth over the past year.
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
March 09, 2023
Regeneron and Sarepta Therapeutics have been on fire so far this year.
Via
The Motley Fool
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
March 06, 2023
The French drug company got the nod for a hemophilia treatment.
Via
The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
March 01, 2023
Via
Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
February 24, 2023
Startling cancer vaccine results from Moderna may point to the next big thing in biotech.
Via
Investor's Business Daily
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
February 03, 2023
Via
Benzinga
Regeneron Pharmaceuticals's Earnings Outlook
February 02, 2023
Via
Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
February 21, 2023
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.
Via
Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
February 14, 2023
These companies have impeccable long-term investment theses.
Via
The Motley Fool
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
February 13, 2023
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.
Via
Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
February 13, 2023
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.
Via
InvestorPlace
New 52-Week Highs In 2023
February 13, 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023.
Via
Talk Markets
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
February 13, 2023
Via
Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
February 10, 2023
Via
Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
February 07, 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.
Via
InvestorPlace
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
February 03, 2023
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.
Via
Investor's Business Daily
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
February 03, 2023
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...
Via
Benzinga
The 7 Most Undervalued Stocks to Buy in February 2023
February 02, 2023
These undervalued stocks to buy are under-appreciated, and have substantial upside as we move deeper into the new year.
Via
InvestorPlace
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
February 02, 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.
Via
InvestorPlace
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
February 01, 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.
Via
InvestorPlace
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.